This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEUVEN, Belgium, July 31, 2014 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that JETREA
® (ocriplasmin) has been nominated for the 2014 Prix Galien USA Award in the Best Biotechnology Product category. This is the second time that JETREA
®, a novel pharmacological treatment for symptomatic vitreomacular adhesion (VMA), has been nominated for this award. This latest nomination follows last month's nomination of JETREA
® for the Prix Galien UK Award.
The Prix Galien USA, now in its eighth year, is an international award that recognizes outstanding achievements in improving human health through the development of innovative therapies. The winner is selected by a committee of nine experts in the biomedical industry and academia, including five Nobel Laureates.
Dr Patrik De Haes, CEO of ThromboGenics, said:
"We are extremely proud that JETREA ® has been nominated for the second time for such a prestigious award. JETREA ® is the first pharmacological option that allows
patients with symptomatic VMA/VMT to have access to earlier treatment. ThromboGenics is committed to working with the global retina community to continue to capture additional real-world data on the optimal use of JETREA ® so that it can be used to assist as many patients as possible around the world who could benefit from this innovative drug."
® is the only drug approved by the US Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA). ThromboGenics launched the drug in the US in mid-January 2013.
® was approved in the European Union in March 2013. Partner Alcon, a division of Novartis, Alcon acquired the rights to commercialize JETREA
® outside the United States in March 2012 and is and is rolling out the drug across Europe and the rest of the world.
EndsFor further information please contact:
About JETREA® (ocriplasmin)
® (ocriplasmin) is a truncated form of human plasmin. In the US, JETREA
® is indicated for the treatment of symptomatic VMA. In Europe, JETREA
® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. JETREA
® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.
JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.